SK Bioscience Co.,Ltd
A vaccine specialist developing in-house products such as SKYCellflu and SKYZoster while also serving as CDMO for AstraZeneca and Novavax.
Price
Change
Market cap
Business overview
Source: DART corporate disclosureEstablished in 2018 through a spin-off of SK Chemicals' vaccine division and listed on KOSPI in 2021, SK Bioscience is a vaccine-focused company. It has developed in-house vaccines including the cell-culture flu vaccines SKYCellflu and SKYCellflu4, the shingles vaccine SKYZoster, the varicella vaccine SKYVaricella, the typhoid conjugate vaccine SKYTyphoid, and the COVID-19 vaccine SKYCovione, while also serving as CDMO for AstraZeneca's Vaxzevria and Novavax's Nuvaxovid. Under a 2014 co-development agreement with Sanofi worth US$45.0M plus EUR350M, it is running a global Phase 3 trial of a 21-valent pneumococcal vaccine in about 9,000 children and adolescents, and has a US$140.0M agreement with CEPI covering the mRNA-based Japanese encephalitis vaccine GBP560.
Products & technology
- SKYCellfluCell-culture trivalent influenza vaccine
- SKYCellflu4Cell-culture quadrivalent influenza vaccine
- SKYZosterShingles vaccine
- SKYVaricellaVaricella vaccine
- SKYTyphoidTyphoid conjugate vaccine
- SKYCovioneCOVID-19 vaccine (GBP510)
Regulatory approvals
data.go.kr18 Korean MFDS drug approvals · 1998–2022
- MFDS drugSkyCovione Multi Injection2022-06-29Drug · Prescription · Approval202202677
- MFDS drugSKYTyphoid multi inj. (Thyphoid purified Vi Polysaccharide Conjugated to Diphtheria toxoid vaccine)2022-05-12Drug · Prescription · Approval202201983
- MFDS drugNUVAXOVID Pre-filled syringe (SARS-CoV-2 Spike Protein Vaccine(Recombinant))2022-01-12Drug · Prescription · Approval202200228
- MFDS drugSKYPneumo Prefilled syringe (Pneumococcal Polysaccharide Conjugated to Diphtheria CRM 197)2021-06-04Drug · Prescription · Approval202104391
- MFDS drugSKYPneumo Prefilled syringe (for export)Revoked2020-05-14Drug · Prescription · Approval202003491
- MFDS drugSKYCellflu Prefilled Syringe (for export)2020-01-10Drug · Prescription · Approval202000160
- MFDS drugSKYCellflu Quadrivalent Prefilled Syringe (0.5mL) (for export)2020-01-09Drug · Prescription · Approval202000155
- MFDS drugSKYCellflu Quadrivalent Multi inj. (surface antigen, inactivated, prepared in cell culture) (for export)2019-02-22Drug · Prescription · Approval201901145
- MFDS drugSKYCellflu Quadrivalent inj. (surface antigen, inactivated, prepared in cell culture) (for export)2019-02-18Drug · Prescription · Approval201900985
- MFDS drugSKYVaricella Inj. (Varicella Virus Vaccine (live) [Oka/SK])2018-06-04Drug · Prescription · Approval201802323
- MFDS drugSKYZoster Vaccine Inj. (Zoster Virus Vaccine (live) [Oka/SK])2017-09-29Drug · Prescription · Approval201707343
- MFDS drugSKYCellflu®Multi inj. (Trivalent Influenza Vaccine) (for export)2017-09-06Drug · Prescription · Approval201706967
Show 6 more
- MFDS drugSKYCellflu®inj. (Trivalent Influenza Vaccine) (for export)2017-03-27Drug · Prescription · Approval201701434
- MFDS drugSKYCellflu Quadrivalent Prefilled Syringe (Surface Antigen, Inactivated, prepared in cell culture)2015-12-24Drug · Prescription · Approval201508425
- MFDS drugSKYCellflu Prefilled Syringe (Surface Antigen, Inactivated, prepared in cell culture)2014-12-26Drug · Prescription · Approval201406070
- MFDS drugHepamun Prefilled Syringe (Hepatitis B Vaccine(rDNA))2012-04-24Drug · Prescription · Approval201203144
- MFDS drugSK Td Vaccine Inj. (Pre-filled Syringe) (Adsorbed Diphtheria-Tetanus combined Toxoid for adult)Revoked2005-02-28Drug · Prescription · Approval200501774
- MFDS drugHepamune Inj. (Hepatitis B Vaccine, recombinant)Revoked1998-11-10Drug · Prescription · Approval199801806
Clinical trials
data.go.kr8 MFDS clinical trial authorisations · 2016–2025 (Phase 3 4 · Phase 1 2 · Phase 1/2 2)
- Phase 3스카이바리셀라주(NBP608)2025-12-16
10 trial sites
- Phase 1NBP18012025-04-14
1 trial site
- Phase 3GBP5102021-08-10
19 trial sites
- Phase 1/2GBP5102021-01-26
15 trial sites
- Phase 1/2GBP5102020-12-31
15 trial sites
- Phase 1NBP20012020-11-23
3 trial sites
- Phase 3SK-NBP607QIV세포배양인플루엔자백신주-4가2018-08-31
12 trial sites
- Phase 3SK-NBP607QIV세포배양인플루엔자백신주-4가2016-10-06
12 trial sites
R&D and key agreements
Source: DART corporate disclosure21가 폐렴구균백신(GBP410) · 폐렴구균 감염증 · 글로벌 임상 3상 · Co-developed with Sanofi since 2014; Phase 3 in ~9,000 children/adolescents from Dec 2024
차세대 폐렴구균백신(NextGen) · 폐렴구균 감염증 · 기초연구/비임상 · Expanded co-development deal with Sanofi (2024)
일본뇌염 mRNA백신(GBP560) · 일본뇌염 · 글로벌 임상 1/2상(2025~) · Co-developed with CEPI since 2022
라싸열 mRNA백신(GBP570) · 라싸열 · 기초연구 · Co-developed with CEPI
범용 사베코바이러스백신(GBP511) · 사베코바이러스 감염증 · 임상 1/2상 IND 승인 · CEPI agreement, Dec 2021, US$65.1M
Nasal Spray 백신 · 임상시료 생산완료/안정성시험 진행중 · IAVI agreement, Nov 2021, US$4M
Companies approved for the same productsBiotech & Drug Discovery
Ranked by how many MFDS product categories overlap. Not a ranking — a pointer to where to look.
A diversified SK group company operating eco-friendly chemical materials alongside pharmaceutical products like Joins and vaccines through subsidiary SK Bioscience.
KOSDAQ-listed integrated security company behind the V3 antivirus and AhnLab TrusGuard and XDR solutions.
Organoid-based biotech founded 2018, KOSDAQ-listed 2025, developing the ATORM-C regenerative therapeutic and ODISEI evaluation solution.
Genomics and drug developer behind the osteoarthritis drug Acelex and the AI-driven healthcare platform Invites Loop.
EDGC, a Korea-US joint venture of Eone Medical Foundation and Diagnomics, offers the NIPT service NICE and liquid biopsy OncoCatch.
KOSDAQ-listed biotech developing biomarker-driven targeted cancer therapies including lead candidate Vabametkib (ABN401).
KOSDAQ-listed antibody biotech developing the next-generation immuno-oncology candidate Multi-AbKine on its fully human antibody library Ymax®-ABL.
KONEX-listed biotech venture developing new drug candidates with its multi-target fusion protein platform NTIG®
Biotech company developing fusion-protein immuno-oncology and allergy therapeutics, listed on KOSDAQ since 2023.
SillaJen, Inc., founded in 2006 and listed on KOSDAQ in 2016, develops the oncolytic virus immunotherapy Pexa-Vec.
An ADC (antibody-drug conjugate) developer with its ConjuALL platform, having licensed pipeline assets to Janssen, Ono Pharmaceutical, and other global partners.
KOSDAQ-listed biopharma developing the BVAC cancer immunotherapy vaccine series and the AdCLD-CoV19-1 COVID-19 vaccine.
Sources and updates
- Company basics
- Korea Exchange · DART
- Business content
- Compiled from disclosure filings
- AI visibility
- Measured 2026-08-13
This page is compiled from public sources without the company's involvement. If anything is inaccurate or incomplete, please let us know. Materials provided by the company are labelled as such.
Request a correction or addition